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Antiphospholipid antibodies (aPL) are both diagnostic
markers for, and pathogenic drivers of, antiphospholipid
syndrome (APS). Beta 2 glycoprotein I (Beta2GPI)-
dependent aPL, the most important subset, mediate dif-
ferent–and not necessarily alternative–thrombogenic
mechanisms, mainly on the basis of their reactivity with
Beta2GPI expressed on cells that participate in the coa-
gulation cascade. In vivo experimental models showed
that Beta2GPI cannot be detected in vascularized organs
in resting conditions, while it can be over-expressed after
pro-inflammatory stimulus. In this condition autoantibo-
dies recognize the molecule, fix complement (C’) and
eventually induce clotting. This finding is in line with the
observation that although the presence of aPL is a neces-
sary pre-condition, APS-associated clotting is triggered
by an additional ‘second hit’, frequently related to innate
inflammatory immune responses.
Recurrent pregnancy complications associated with
aPL cannot be explained solely by thrombosis, and alter-
native pathogenic mechanisms have been reported.
Although one in vivo model of fetal loss supports a
mechanism of aPL-mediated acute placental inflamma-
tion, other models and the histopathological examination
of APS placentae do not support an inflammatory signa-
ture. Beta2GPI can be detected on endothelial cells of
uterine vessels in resting conditions and its presence is
increased during pregnancy in uterine endothelium and
trophoblast. This finding does support the hypothesis
that Beta2GPI -dependent aPL recognize their antigen on
placental tissues. There is evidence that the antibodies
may inhibit the growth and differentiation of tropho-
blasts, and eventually cause defective placentation so
explaining the APS obstetric manifestations.
Why antibodies with similar antigen specificity produce
different clinical manifestations is not clear. The formation
of immune complexes on the membrane of cells with dif-
ferent biological functions may at least in part explain the
diverse effects mediated by the autoantibodies (i.e. clotting
versus defective placentation). Altogether this finding
strongly supports the pivotal role of Beta2GPI as the main
tissue target for aPL. Accordingly, new approaches have
been tried in order to interfere with the antibody binding
and its consequences. A synthetic peptide displaying a
similarity in the PL-binding region of the Vth domain of
the Beta2GPI was shown to compete with the molecule
binding to the membrane of cells involved in the patho-
genesis of the syndrome (i.e. endothelial cells, monocytes
and trophoblasts). The passive infusion of the peptide was
protective against the effect of polyclonal human APS IgG
fractions on experimental thrombus formation and fetal
loss induction. Moreover, a human monoclonal antibody
against the immunodominant epitope of the Beta2GPI
(Domain I) was shown to induce fetal loss and to trigger
clotting by fixing C’ in naïve mice. A similar monoclonal
antibody lacking the CH2 fragment in the Fc gamma por-
tion was still reacting with the Beta2GPI but no more able
to activate C’. The C’ non-fixing monoclonal antibody was
protective by competing with the pathogenic one when
passively infused in naïve mice and evaluated for both the
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